Your browser doesn't support javascript.
loading
The Global Burden of Cancer 2013.
Fitzmaurice, Christina; Dicker, Daniel; Pain, Amanda; Hamavid, Hannah; Moradi-Lakeh, Maziar; MacIntyre, Michael F; Allen, Christine; Hansen, Gillian; Woodbrook, Rachel; Wolfe, Charles; Hamadeh, Randah R; Moore, Ami; Werdecker, Andrea; Gessner, Bradford D; Te Ao, Braden; McMahon, Brian; Karimkhani, Chante; Yu, Chuanhua; Cooke, Graham S; Schwebel, David C; Carpenter, David O; Pereira, David M; Nash, Denis; Kazi, Dhruv S; De Leo, Diego; Plass, Dietrich; Ukwaja, Kingsley N; Thurston, George D; Yun Jin, Kim; Simard, Edgar P; Mills, Edward; Park, Eun-Kee; Catalá-López, Ferrán; deVeber, Gabrielle; Gotay, Carolyn; Khan, Gulfaraz; Hosgood, H Dean; Santos, Itamar S; Leasher, Janet L; Singh, Jasvinder; Leigh, James; Jonas, Jost B; Jonas, Jost; Sanabria, Juan; Beardsley, Justin; Jacobsen, Kathryn H; Takahashi, Ken; Franklin, Richard C; Ronfani, Luca; Montico, Marcella.
Afiliação
  • Fitzmaurice C; Division of Hematology, Department of Medicine, University of Washington, Seattle2Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Dicker D; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Pain A; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Hamavid H; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Moradi-Lakeh M; Institute for Health Metrics and Evaluation, University of Washington, Seattle3Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • MacIntyre MF; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Allen C; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Hansen G; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Woodbrook R; Institute for Health Metrics and Evaluation, University of Washington, Seattle.
  • Wolfe C; King's College London, London, England.
  • Hamadeh RR; Arabian Gulf University, Manama, Bahrain.
  • Moore A; University of North Texas, Denton.
  • Werdecker A; Institute of Medical Sociology and Social Medicine, Marburg, Germany.
  • Gessner BD; Agence de Medecine Preventive, Paris, France.
  • Te Ao B; Department of Biostatistics and Epidemiology, School of Public Health and Psychosocial Studies, Auckland University of Technology, Auckland, New Zealand.
  • McMahon B; Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
  • Karimkhani C; College of Physicians and Surgeons, Columbia University, New York, New York.
  • Yu C; Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China.
  • Cooke GS; Imperial College London, London, England.
  • Schwebel DC; Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama.
  • Carpenter DO; Institute for Health and the Environment, University at Albany, Rensselaer, New York.
  • Pereira DM; Laboratório de Farmacognosia, Departamento de Ciências Químicas, Faculdade de Farmácia, University do Porto, REQUIMTE/LAQV, Porto, Portugal.
  • Nash D; School of Public Health, Hunter College Campus, City University of New York, New York.
  • Kazi DS; University of California, San Francisco.
  • De Leo D; Griffith University, Brisbane, Australia.
  • Plass D; Federal Environment Agency Section on Exposure Assessment and Environmental Health Indicators, Berlin, Germany.
  • Ukwaja KN; Department of Internal Medicine, Federal Teaching Hospital, Abakaliki, Nigeria.
  • Thurston GD; Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York.
  • Yun Jin K; Faculty of Chinese Medicine, Southern University College, Johor, Malaysia.
  • Simard EP; Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Mills E; University of Ottawa, Ottawa, Ontario, Canada.
  • Park EK; Department of Medical Humanities and Social Medicine, Kosin University College of Medicine, Busan, South Korea.
  • Catalá-López F; Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Medicines and Healthcare Products Agency (AEMPS), Ministry of Health, Madrid, Spain.
  • deVeber G; University of Toronto, Toronto, Ontario, Canada.
  • Gotay C; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
  • Khan G; Department of Microbiology & Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates.
  • Hosgood HD; Albert Einstein College of Medicine, Bronx, New York.
  • Santos IS; Centre for Clinical and Epidemiological Research, University of São Paulo, São Paulo, Brazil.
  • Leasher JL; Nova Southeastern University, Fort Lauderdale, Florida.
  • Singh J; Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama.
  • Leigh J; University of Sydney, Sydney, Australia.
  • Jonas JB; Department of Ophthalmology, University of Heidelberg, Mannheim, Germany.
  • Sanabria J; Department of Surgery, Case Western Reserve University, Cleveland, Ohio38Nutrition and Preventive Medicine, Chicago Medical School at Cancer Treatment Centers of America, Rosalind Franklin University, Chicago, Illinois.
  • Beardsley J; Nuffield Department of Medicine, Oxford University, Ho Chi Minh City, Vietnam.
  • Jacobsen KH; Department of Global and Community Health, George Mason University, Fairfax, Virginia.
  • Takahashi K; Department of Environmental Epidemiology, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Franklin RC; College of Public Health, Medical and Veterinary Sciences, James Cook University, Townsville, Australia.
  • Ronfani L; Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  • Montico M; Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
JAMA Oncol ; 1(4): 505-27, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26181261
ABSTRACT
IMPORTANCE Cancer is among the leading causes of death worldwide. Current estimates of cancer burden in individual countries and regions are necessary to inform local cancer control strategies.

OBJECTIVE:

To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex from 1990 to 2013. EVIDENCE REVIEW The general methodology of the Global Burden of Disease (GBD) 2013 study was used. Cancer registries were the source for cancer incidence data as well as mortality incidence (MI) ratios. Sources for cause of death data include vital registration system data, verbal autopsy studies, and other sources. The MI ratios were used to transform incidence data to mortality estimates and cause of death estimates to incidence estimates. Cancer prevalence was estimated using MI ratios as surrogates for survival data; YLDs were calculated by multiplying prevalence estimates with disability weights, which were derived from population-based surveys; YLLs were computed by multiplying the number of estimated cancer deaths at each age with a reference life expectancy; and DALYs were calculated as the sum of YLDs and YLLs.

FINDINGS:

In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries. CONCLUSIONS AND RELEVANCE Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening, treatment, and palliation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Saúde Global / Neoplasias Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Saúde Global / Neoplasias Idioma: En Ano de publicação: 2015 Tipo de documento: Article